
|Podcasts|November 16, 2021
Facilitating Decentralized Clinical Trials with the Direct-to-Patient Trial Strategy
Author(s)YPrime
A direct-to-patient (DtP) clinical trial design, where investigational medicinal products (IMP) and clinical supplies are shipped or delivered directly to patients, fits within a decentralized clinical trial (DCT) model. Although patients, sites, and sponsors can all benefit from this trial design, there are unique complexities to DtP trials, that can be managed with advanced technology. Learn about this trial strategy, the unique challenges, what the industry is doing to address these challenges and how technology can help facilitate adoption of this trial design.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
ACT Brief: Data Quality as Foundational to Trial Modernization, CRAs Evolving to Strategic Site Partners, and 2026 Emerging Pharma Leaders Announced
2
Survey Finds US Biotechs Prefer Domestic First-in-Human Trials but FDA Hurdles Are Pushing Them Abroad
3
Tufts CSDD Analysis Finds AI Clinical Monitoring Agent Can Generate Up to $21 Million in Net Financial Value Per Drug Development Program
4
Breaking the Efficacy Ceiling in IBD and Beyond
5



